Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,824 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Media Clear all

Conditions: SARS-CoV-2 Infection
Interventions: Vitamin D3; Dietary Supplement
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 1,475 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Otitis Media, Otitis Media With Effusion, Otitis Media Acute
Interventions: OCT Device(s); Diagnostic Test
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 12 Months to 6 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Wauwatosa, Wisconsin

Conditions: Hyperlipidemia
Interventions: MCT oil + Butter in Coffee; Dietary Supplement
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis, Candidiasis, Aspergillosis
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 12,032 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Irritable Bowel Syndrome
Interventions: Olorinab, Placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 69
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more

Conditions: Venous Stasis Ulcers
Interventions: PEMF therapy with a high-power PEMF device, PEMF therapy with a medium PEMF power device, PEMF therapy with a low-power PEMF device, PEMF therapy with the sham PEMF device; Device
Lead sponsor: PEMF Systems, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Abdominal Obesity, Growth Hormone Deficiency
Interventions: Growth hormone releasing hormone (GHRH) 1-44, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypophosphatasia
Interventions: ALXN1850; Biological
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Las Vegas, Nevada • Columbus, Ohio • Nashville, Tennessee + 1 more

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: MART-1 antigen, gp100:209-217(210M) peptide vaccine, therapeutic autologous dendritic cells, tyrosinase peptide; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 16 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: Los Angeles, California • Ann Arbor, Michigan

Conditions: Ovarian Carcinoma
Interventions: Dietary Intervention, Media Intervention, Telephone-Based Intervention; Dietary Supplement · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Preexposure Prophylaxis, HIV Infections
Interventions: GYN Residency Training, Social Media Campaign; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hemophilia A, Prophylaxis of Bleeding
Interventions: Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).; Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: Loma Linda, California • Los Angeles, California • Aurora, Colorado + 8 more

Conditions: Renal Insufficiency, Diabetes Mellitus
Interventions: Iodixanol 320-Arm 1, Iopamidol 300-Arm 2; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 1,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 59
States / cities: Mobile, Alabama • Gilbert, Arizona • Mesa, Arizona + 53 more

Conditions: Dry Needling
Interventions: Delphi Questionaire; Other
Lead sponsor: Youngstown State University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Youngstown, Ohio

Conditions: Gut Microbiome, Neurocognitive Correlates of Eating Habits, Infant Growth
Interventions: Daily avocado; Other
Lead sponsor: Arizona State University; Other
Eligibility: 3 Months to 6 Months
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Alzheimer's Disease
Interventions: Posiphen, Placebo; Drug
Lead sponsor: Annovis Bio Inc.; Industry
Eligibility: 55 Years to 89 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: La Jolla, California • Indianapolis, Indiana • Baltimore, Maryland + 3 more

Conditions: Cardiovascular Disease
Interventions: GSK2212836; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Acute Otitis Media
Interventions: amoxicillin-clavulanate, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Months to 23 Months
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BI 1744 CL/tiotropium bromide fixed dose combination, tiotropium bromide, Respimat® Inhaler; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 22
States / cities: Riverside, California • San Diego, California • Wheat Ridge, Colorado + 18 more

Conditions: Malnutrition, Child
Interventions: Smoflipid, Intralipid, 20%; Drug
Lead sponsor: Fresenius Kabi; Industry
Eligibility: 3 Months to 16 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sexual Behavior, Communication
Interventions: Web-based resource on adolescent sexual health, Alternate web-based resource on adolescent sexual health; Behavioral
Lead sponsor: Innovation Research & Training; Other
Eligibility: Not listed
Enrollment: 730 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Schizophrenia, Cannabis Use Disorder
Interventions: Delta-9-THC Very Low Dose, Placebo, Delta-9-THC Medium Dose; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 215 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Cystic Fibrosis
Interventions: VX-121, TEZ, VX-561, TEZ/IVA, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 12
States / cities: Los Angeles, California • Oakland, California • Lexington, Kentucky + 9 more

Search by objective public record fields.

Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19

Coherent Optical Detection of Middle Ear Disease

Effect of Butter & MCT Oil on Lipoproteins - A RCT

Prospective Observational Study on the Incidence of Opportunistic Fungal Infections

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

The Effects of Pulsed Elelectro-Magnetic Fields ("PEMF") in the Treatment of Venous Stasis Leg Ulcers

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

Study of ALXN1850 in Participants With Hypophosphatasia (HPP)

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy

Start the Conversation: Evaluating Implementation of a Multi-level PrEP Initiative for Black Cisgender Women in Nola

Prophylaxis Regimen for Hemophilia A Patients

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Identifying Which Adverse Events Associated With Dry Needling Should be Included For Informed Consent: A Modified e-Delphi Study

Early Avocado Exposure on Development and the Gut Microbiome in American Hispanic Infants

Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.

Acute Otitis Media (AOM) Therapy Trial in Young Children

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age

Birds and Bees Research Study

Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis